Structure-activity relationships of a series of analogues of the RFamide-related peptide 26RFa.

26RFa is a new member of the RFamide peptide family that has been identified as the endogenous ligand of the orphan GPCR GPR103. As the C-terminal heptapeptide (26RFa((20-26))) mimics the action of the native peptide on food intake and gonadotropin secretion in rodents, we have synthesized a series of analogues of 26RFa((20-26)) and measured their potency to induce [Ca(2+)](i) mobilization in Gα(16)-hGPR103-transfected CHO cells. Systematic replacement of each residue by an alanine (Ala scan) and its D-enantiomer (D scan) showed that the last three C-terminal residues were very sensitive to the substitutions while position 23 tolerated rather well both modifications. Most importantly, replacement of Ser(23) by a norvaline led to an analogue, [Nva(23)]26RFa((20-26)), that was 3-fold more potent than the native heptapeptide. These new pharmacological data, by providing the first information regarding the structure-activity relationships of 26RFa analogues, should prove useful for the rational design of potent GPR103 receptor ligands with potential therapeutic application.

[1]  H. Vaudry,et al.  Molecular evolution and functional characterization of the orexigenic peptide 26RFa and its receptor in vertebrates , 2011, Cell and Tissue Research.

[2]  M. Vidal,et al.  Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. , 2010, Journal of medicinal chemistry.

[3]  H. Vaudry,et al.  Identification, localization, and function of a novel avian hypothalamic neuropeptide, 26RFa, and its cognate receptor, G protein-coupled receptor-103. , 2010, Endocrinology.

[4]  Toshihiko Yamada,et al.  Intracerebroventricular administration of 26RFa produces an analgesic effect in the rat formalin test , 2009, Peptides.

[5]  G. Bray,et al.  Central administration of the RFamide peptides, QRFP-26 and QRFP-43, increases high fat food intake in rats , 2008, Peptides.

[6]  A. E. Curtis,et al.  Pyroglutamylated RFamide peptide 43 stimulates the hypothalamic-pituitary-gonadal axis via gonadotropin-releasing hormone in rats. , 2008, Endocrinology.

[7]  H. Vaudry,et al.  Novel stable PACAP analogs with potent activity towards the PAC1 receptor , 2008, Peptides.

[8]  H. Vaudry,et al.  Distribution of 26RFa binding sites and GPR103 mRNA in the central nervous system of the rat , 2007, The Journal of comparative neurology.

[9]  H. Vaudry,et al.  26RFa, a novel orexigenic neuropeptide, inhibits insulin secretion in the rat pancreas , 2007, Peptides.

[10]  H. Vaudry,et al.  Functional differences between NPFF1 and NPFF2 receptor coupling: High intrinsic activities of RFamide-related peptides on stimulation of [35S]GTPγS binding , 2007, Neuropharmacology.

[11]  K. Lumb,et al.  Engineering of a VPAC2 receptor peptide agonist to impart dipeptidyl peptidase IV stability and enhance in vivo glucose disposal. , 2006, Journal of medicinal chemistry.

[12]  H. Vaudry,et al.  Behavioral effects of 26RFamide and related peptides , 2006, Peptides.

[13]  H. Vaudry,et al.  Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist. , 2006, Journal of medicinal chemistry.

[14]  H. Vaudry,et al.  Anatomical distribution and biochemical characterization of the novel RFamide peptide 26RFa in the human hypothalamus and spinal cord , 2006, Journal of neurochemistry.

[15]  H. Iwaasa,et al.  RFamide peptide QRFP43 causes obesity with hyperphagia and reduced thermogenesis in mice. , 2006, Endocrinology.

[16]  A. Yamanaka,et al.  A neuropeptide ligand of the G protein-coupled receptor GPR103 regulates feeding, behavioral arousal, and blood pressure in mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Vaudry,et al.  Novel role of 26RFa, a hypothalamic RFamide orexigenic peptide, as putative regulator of the gonadotropic axis , 2006, The Journal of physiology.

[18]  W. Richards,et al.  The G-Protein-Coupled Receptor GPR103 Regulates Bone Formation , 2006, Molecular and Cellular Biology.

[19]  J. Dognon,et al.  Gas-phase models of gamma turns: effect of side-chain/backbone interactions investigated by IR/UV spectroscopy and quantum chemistry. , 2005, The Journal of chemical physics.

[20]  H. Vaudry,et al.  Structural studies on 26RFa, a novel human RFamide-related peptide with orexigenic activity , 2005, Peptides.

[21]  J. Humphries,et al.  Structure‐activity studies on prolactin‐releasing peptide (PrRP). Analogues of PrRP‐(19–31)‐peptide , 2005, Journal of peptide science : an official publication of the European Peptide Society.

[22]  Hassan Oulyadi,et al.  Structure–activity relationships and structural conformation of a novel urotensin II-related peptide , 2004, Peptides.

[23]  F. Vandesande,et al.  Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Hinuma,et al.  A New Peptidic Ligand and Its Receptor Regulating Adrenal Function in Rats* , 2003, Journal of Biological Chemistry.

[25]  James F. Riordan,et al.  Ace revisited: A new target for structure-based drug design , 2003, Nature Reviews Drug Discovery.

[26]  F. Monsma,et al.  Identification and Characterization of a Novel RF-amide Peptide Ligand for Orphan G-protein-coupled Receptor SP9155* , 2003, Journal of Biological Chemistry.

[27]  Pierre Renard,et al.  Structure–Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction , 2003, Journal of enzyme inhibition and medicinal chemistry.

[28]  J. Boutin,et al.  Cloning and molecular characterization of the novel human melanin-concentrating hormone receptor MCH2. , 2001, Molecular pharmacology.

[29]  C. Mollereau,et al.  Structure-activity relationships of neuropeptide FF: role of C-terminal regions , 2001, Peptides.

[30]  H. Vaudry,et al.  Structure-activity relationships of a series of analogues of the octadecaneuropeptide ODN on calcium mobilization in rat astrocytes. , 1998, Journal of medicinal chemistry.

[31]  C. Deber,et al.  Erratum: A measure of helical propensity for amino acids in membrane environments , 1994, Nature Structural Biology.

[32]  C. Strader,et al.  Determination of the amino acid residues in substance P conferring selectivity and specificity for the rat neurokinin receptors. , 1992, Molecular pharmacology.

[33]  Robert L. Baldwin,et al.  Relative helix-forming tendencies of nonpolar amino acids , 1990, Nature.

[34]  K. Kawai,et al.  Stimulation of dog gastropancreatic hormone release by neuromedin B and its analogues. , 1987, The American journal of physiology.

[35]  E. Escher,et al.  Structure-activity studies on the C-terminal amide of substance P. , 1982, Journal of medicinal chemistry.

[36]  G. Handelmann,et al.  N-acetylation regulates the behavioral activity of alpha-melanotropin in a multineurotransmitter neuron. , 1982, Science.

[37]  K. Wagner,et al.  Conformational properties of L‐leucine, L‐isoleucine, and L‐norleucine side chains in L‐lysine copolymers , 1977, Biopolymers.

[38]  H. Vaudry,et al.  The RFamide-Related Peptides , 2006 .

[39]  R. Mains,et al.  The biosynthesis of neuropeptides: peptide alpha-amidation. , 1992, Annual review of neuroscience.

[40]  J. Fauchère,et al.  Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design , 1992 .